芬在心力衰竭中的作用
Hassan Ismahel1, Kieran F Docherty1
1BHF Cardiovascular Research Centre, University of Glasgow, Glasgow, Scotland, UK.
Trends in cardiovascular medicine
|May 18, 2025
概括
菲内伦是一种选择性矿物质皮质类受体对抗剂,为心力衰竭提供了一种新的治疗选择,该疗法具有轻微减少或保存的射出分数 (HFmrEF/HFpEF). 临床试验表明,这些患者的芬瑞龙减少了心血管事件和住院治疗.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
- 腎臟病學 (nephrology) 是一種醫學專業.
背景情况:
- 轻微减少或保留喷射分数 (HFmrEF/HFpEF) 的心力衰竭影响许多患者,治疗选择有限.
- 矿物质皮质类受体 (MR) 的过度活化导致心脏纤维化,炎症和HFmrEF/HFpEF中的过度缩小.
- 菲内伦是一种新型的非类固醇MR抗剂,具有强大的选择性和减少副作用.
研究的目的:
- 审查在管理HFmrEF/HFpEF时使用finerenone的证据.
- 为了突出fineerenone在治疗心血管疾病中MR过度激活方面的作用.
主要方法:
- 关键随机对照试验的审查 (菲德利奥-DKD,菲加罗-DKD,FINEARTS-HF).
- 分析费内伦的药理特征和临床结果.
- 包括正在进行和计划中的研究 (REDEFINE-HF,CONFIRMATION-HF,FINALITY-HF).
主要成果:
- 芬瑞在CKD和T2D患者中显示出心脏和脏的益处.
- 在FINEARTS-HF试验中,finerenone在HFmrEF/HFpEF中减少了HF恶化事件和心血管死亡.
- 菲内伦的选择性MR阻塞提供了有利的安全性.
结论:
- 菲内伦代表了HFmrEF/HFpEF治疗的重大进步.
- 证据支持在多种高频率人群中使用finerenone的有效性和安全性.
- 进一步的研究将确定fineerenone在HF频谱中的作用.
更多相关视频
07:09A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs
Published on: February 18, 2022
1.5K
08:505/6th Nephrectomy in Combination with High Salt Diet and Nitric Oxide Synthase Inhibition to Induce Chronic Kidney Disease in the Lewis Rat
Published on: July 3, 2013
23.5K
相关概念视频
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
347
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
347
01:22Heart Failure Drugs: Diuretics
306
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
306
01:22Heart Failure Drugs: β-Blockers
295
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
295
01:26Heart Failure Drugs: Inotropic Agents
469
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
469
01:17Pathophysiology of Heart Failure
1.4K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.4K
01:11Renal Failure: Dose Adjustments
50
In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
50